Abstract:Background: Special AT-rich sequence-binding protein-1 (SATB1) has been reported to be expressed in several human cancers and may have malignant potential. This study was aimed at investigating the expression and potential role of SATB1 in human glioma.Method: The relationship between SATB1 expression, clinicopathological parameters, Ki67 expression and MGMT promoter methylation status was evaluated, and the prognostic value of SATB1 expression in patients with gliomas was analyzed. SATB1-specific shRNA sequences were synthesized, and U251 cells were transfected with SATB1 RNAi plasmids. Expression of SATB1 mRNA and protein was investigated by RT-PCR and immunofluoresence staining and western blotting. The expression of c-Met, SLC22A18, caspase-3 and bcl-2 protein was determined by western blotting. U251 cell growth and adherence was detected by methyl thiazole tetrazolium assay. The apoptosis of U251 cells was examined with a flow cytometer. The adherence, invasion, and in vitro angiogenesis assays of U251 cells were done. The growth and angiogenesis of SATB1 low expressing U251 cells was measured in an in vivo xenograft model.Results: Of 70 tumors, 44 (62.9%) were positive for SATB1 expression. SATB1 expression was significantly associated with a high histological grade and with poor survival in univariate and multivariate analyses. SATB1 expression was also positively correlated with Ki67 expression but negatively with MGMT promoter methylation in glioma tissues. SATB1 shRNA expression vectors could efficiently induce the expression of SLC22A18 protein, increase the caspase-3 protein, inhibit the expression of SATB1, c-Met and bcl-2 protein, the growth, invasion, metastasis and angiogenesis of U251 cells, and induce apoptosis in vitro. Furthermore, the tumor growth of U251 cells expressing SATB1 shRNA were inhibited in vivo, and immunohistochemical analyses of tumor sections revealed a decreased vessel density in the animals where shRNA against SATB1 were expressed.Conclusions: SATB1 may have an important role as a positive regulator of glioma development and progression, and that SATB1 might be a useful molecular marker for predicting the prognosis of glioma.

SATB1 is an Independent Prognostic Marker for Gastric Cancer in a Chinese Population

Special AT-rich Sequence-Binding Protein 1 Promotes Cell Growth and Metastasis in Colorectal Cancer.

Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features.

Expression of SATB1 Promotes the Growth and Metastasis of Colorectal Cancer

Satb1 Expression Is Associated With Biologic Behavior In Colorectal Carcinoma In Vitro And In Vivo

Special AT-rich Sequence Binding Protein 1 Regulates the Multidrug Resistance and Invasion of Human Gastric Cancer Cells.

Upregulation of SATB1 is Associated with the Development and Progression of Glioma

Overexpression of SATB1 in laryngeal squamous cell carcinoma.

GSE1 Predicts Poor Survival Outcome in Gastric Cancer Patients by SLC7A5 Enhancement of Tumor Growth and Metastasis.

Satb1 Overexpression Correlates with Gastrointestinal Neoplasms Invasion and Metastasis: A Meta-Analysis for Chinese Population

Prognostic Value of SATB2 Expression in Patients with Esophageal Squamous Cell Carcinoma.

SATB1 is Correlated with Progression and Metastasis of Breast Cancers: A Meta-Analysis.

Relationship Between SATB1 Expression and Prognosis in Astrocytoma

Expression of SATB1 in breast cancer and its relationship with clinicopathological features

At-Rich Sequence Binding Protein 1: Contribution to Tumor Progression and Metastasis of Human Ovarian Carcinoma

Overexpression of SATB1 Correlates with Epithelial-Mesenchymal Transition and Lymphatic Metastasis in Gastric Cancer.

Special AT-rich DNA-binding Protein-1 Expression is Associated with Liver Cancer Metastasis

Correlation of SATB1 Overexpression with the Progression of Human Rectal Cancer

Expression of SATB1 and its clinicopathologic significance in colorectal cancer

Poor Prognosis And Satb1 Overexpression In Solid Tumors: A Meta-Analysis

Decreased SATB 2 Expression is Associated with Metastasis and Poor Prognosis in Human Clear Cell Renal Cell Carcinoma